Literature DB >> 3763266

Illness with fatalities in premature infants: association with an intravenous vitamin E preparation, E-Ferol.

W J Martone, W W Williams, M L Mortensen, R P Gaynes, J W White, V Lorch, M D Murphy, S N Sinha, D J Frank, N Kosmetatos.   

Abstract

Three clusters of an unusual syndrome in premature infants were investigated in three intensive care nurseries in 1984. A retrospective cohort study of 68 infants weighing less than or equal to 1,250 g at birth and surviving at least 72 hours revealed that in 13 infants ascites developed and in four at least two of the following abnormal laboratory values were found within a seven-day period: serum direct bilirubin greater than or equal to 2 mg/dL, blood urea nitrogen greater than or equal to 40 mg/dL or serum creatinine greater than or equal to 2 mg/dL, and platelet count less than or equal to 60,000/microL. All cases occurred after the introduction and use of intravenous E-Ferol, a vitamin E preparation that was new on the market when the clusters were reported. All 17 case infants but only 23 of 51 (45%) noncase infants received E-Ferol (P less than .0001). Case and noncase infants were similar with respect to other complications and to receipt of medications and parenteral nutrition. A dose-response relationship was found; cases occurred in infants receiving E-Ferol dosages of greater than 20 U/kg/d. Case infants who had higher daily doses of E-Ferol had a shorter latency. No new cases were reported after use of E-Ferol was stopped. Results of these investigations led to a nationwide recall of intravenous E-Ferol.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3763266

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  6 in total

Review 1.  Advances in the use of tocols as drug delivery vehicles.

Authors:  Panayiotis P Constantinides; Jihong Han; Stanley S Davis
Journal:  Pharm Res       Date:  2006-01-25       Impact factor: 4.200

Review 2.  Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II).

Authors:  L K Golightly; S S Smolinske; M L Bennett; E W Sutherland; B H Rumack
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

Review 3.  Therapeutic challenges. Prenatal and paediatric safety considerations.

Authors:  R E Kauffman
Journal:  Drug Saf       Date:  1990       Impact factor: 5.606

4.  Effects of polysorbates and Cremophor EL on vascular responses in rat aorta.

Authors:  H Zengil; U Hodoğlugil; Z Güney
Journal:  Experientia       Date:  1995-11-15

5.  Pediatric Safety of Polysorbates in Drug Formulations.

Authors:  Christina Kriegel; Matthias Festag; Ravuri S K Kishore; Dieter Roethlisberger; Georg Schmitt
Journal:  Children (Basel)       Date:  2019-12-20

6.  Acute Liver and Renal Failure: A Rare Adverse Effect Exclusive to Intravenous form of Amiodarone.

Authors:  Robin Paudel; Prerna Dogra; Saurav Suman; Saurav Acharya; Jyoti Matta
Journal:  Case Rep Crit Care       Date:  2016-09-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.